Drugs that boost the white blood cells are considered to be safe during concurrent chemoradiotherapy of lung cancer treatment, finds a breaking analysis from the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC). Lung cancer occurs due to the uncontrolled growth of the cancer cells in the lungs.
